111614
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
基于微针和金属酚纳米酶的集成式颜色传感平台用于乙酰胆碱酯酶活性及其药物抑制剂的即时检测
Authors Chen E, Chang P, Xu H, Xu H, Zhu Z , Shen D
Received 25 September 2025
Accepted for publication 1 December 2025
Published 7 December 2025 Volume 2025:20 Pages 14629—14642
DOI https://doi.org/10.2147/IJN.S565467
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Prof. Dr. RDK Misra
Erlin Chen,1 Peng Chang,2 Haibin Xu,2 Hongxing Xu,2 Zhiqiang Zhu,3 Danfeng Shen2
1Department of General Surgery, Affiliated Hospital of Nantong University, Medical College of Nantong University, Nantong, 226000, People’s Republic of China; 2Department of General Surgery, Taicang Affiliated Hospital of Soochow University, Suzhou, 215400, People’s Republic of China; 3School of Biomedical Sciences, Suzhou Chien-Shiung Institute of Technology, Suzhou, 215411, People’s Republic of China
Correspondence: Danfeng Shen, Department of General Surgery, Taicang Affiliated Hospital of Soochow University, Suzhou, 215400, People’s Republic of China, Email danfengsh@hotmail.com Hongxing Xu, Department of General Surgery, Taicang Affiliated Hospital of Soochow University, Suzhou, 215400, People’s Republic of China, Email hongxingxu0601@hotmail.com
Introduction: The detection of acetylcholinesterase (AChE) activity and the screening of its inhibitors are of significant importance for the diagnosis and drug therapy of nervous system diseases, particularly neurodegenerative disorders. This study aimed to develop a novel, integrated point-of-care testing (POCT) platform to address this need.
Methods: We designed and integrated a colorimetric biosensor (Colorisensor) that combines a microneedle array with a metal-phenol nanozyme. The core sensing element is Iron (III)-polydopamine (Fe-PD) nanorods, which exhibit high peroxidase-like activity. The detection mechanism is based on the AChE-catalyzed hydrolysis of acetylthiocholine (ATCh) to produce thiocholine (TCh), which inhibits the nanozyme’s activity. This inhibition prevents the catalytic oxidation of the chromogenic substrate TMB, leading to a measurable color change. A smartphone was utilized to quantify this change via red, green, and blue (RGB) values, creating a rapid and user-friendly platform for detections of AChE activity and its drug inhibitor. The nanorods and microneedle arrays were characterized using scanning electron microscopy, high-resolution transmission electron microscopy, energy-dispersive X-ray spectroscopy, ultraviolet-visible spectrophotometer, water absorption expansion rate, as well as mechanical property tests.
Results and Discussion: The proposed Colorisensor demonstrated excellent analytical performance, including high selectivity and sensitivity with a low detection limit (LOD) of 0.007 mU/mL and a broad linear range from 0.01 to 1000 mU/mL. It was successfully applied to screen berberine hydrochloride as an AChE inhibitor. Crucially, the Colorisensor showed comparable accuracy to the standard Ellman’s method and outperformed both traditional assays and emerging nanomaterial-based colorimetric methods by offering a wider detection range and a lower LOD.
Conclusion: This study presents a successful proof-of-concept for an integrated microneedle and nanozyme-based Colorisensor. The platform provides a viable and promising alternative pathway for the early diagnosis of neurodegenerative diseases and the screening of therapeutic drugs, highlighting its significant potential for point-of-care applications.
Plain Language Summary: ● Facile Fe-PD nanorods hold high POD-like catalyticity for AChE colorimetric analysis.
● High sensitivity and accuracy could be achieved by nanozyme-based Colorisensors.
● Microneedle array integration enables point-of-care testings of AChE and berberine.
Keywords: microneedle, metal-phenol nanozyme, point-of-care testings, acetylcholinesterase, drug inhibitor, colorimetric sensor
1Department of General Surgery, Affiliated Hospital of Nantong University, Medical College of Nantong University, Nantong, 226000, People’s Republic of China; 2Department of General Surgery, Taicang Affiliated Hospital of Soochow University, Suzhou, 215400, People’s Republic of China; 3School of Biomedical Sciences, Suzhou Chien-Shiung Institute of Technology, Suzhou, 215411, People’s Republic of China
Correspondence: Danfeng Shen, Department of General Surgery, Taicang Affiliated Hospital of Soochow University, Suzhou, 215400, People’s Republic of China, Email danfengsh@hotmail.com Hongxing Xu, Department of General Surgery, Taicang Affiliated Hospital of Soochow University, Suzhou, 215400, People’s Republic of China, Email hongxingxu0601@hotmail.com
Introduction: The detection of acetylcholinesterase (AChE) activity and the screening of its inhibitors are of significant importance for the diagnosis and drug therapy of nervous system diseases, particularly neurodegenerative disorders. This study aimed to develop a novel, integrated point-of-care testing (POCT) platform to address this need.
Methods: We designed and integrated a colorimetric biosensor (Colorisensor) that combines a microneedle array with a metal-phenol nanozyme. The core sensing element is Iron (III)-polydopamine (Fe-PD) nanorods, which exhibit high peroxidase-like activity. The detection mechanism is based on the AChE-catalyzed hydrolysis of acetylthiocholine (ATCh) to produce thiocholine (TCh), which inhibits the nanozyme’s activity. This inhibition prevents the catalytic oxidation of the chromogenic substrate TMB, leading to a measurable color change. A smartphone was utilized to quantify this change via red, green, and blue (RGB) values, creating a rapid and user-friendly platform for detections of AChE activity and its drug inhibitor. The nanorods and microneedle arrays were characterized using scanning electron microscopy, high-resolution transmission electron microscopy, energy-dispersive X-ray spectroscopy, ultraviolet-visible spectrophotometer, water absorption expansion rate, as well as mechanical property tests.
Results and Discussion: The proposed Colorisensor demonstrated excellent analytical performance, including high selectivity and sensitivity with a low detection limit (LOD) of 0.007 mU/mL and a broad linear range from 0.01 to 1000 mU/mL. It was successfully applied to screen berberine hydrochloride as an AChE inhibitor. Crucially, the Colorisensor showed comparable accuracy to the standard Ellman’s method and outperformed both traditional assays and emerging nanomaterial-based colorimetric methods by offering a wider detection range and a lower LOD.
Conclusion: This study presents a successful proof-of-concept for an integrated microneedle and nanozyme-based Colorisensor. The platform provides a viable and promising alternative pathway for the early diagnosis of neurodegenerative diseases and the screening of therapeutic drugs, highlighting its significant potential for point-of-care applications.
Plain Language Summary: ● Facile Fe-PD nanorods hold high POD-like catalyticity for AChE colorimetric analysis.
● High sensitivity and accuracy could be achieved by nanozyme-based Colorisensors.
● Microneedle array integration enables point-of-care testings of AChE and berberine.
Keywords: microneedle, metal-phenol nanozyme, point-of-care testings, acetylcholinesterase, drug inhibitor, colorimetric sensor